Introduction: Inebilizumab (INEB), an anti-CD19 B cell-depleting antibody, is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults seropositive for aquaporin-4 antibody (AQP4+). Objectives: To evaluate long-term outcomes of INEB treatment in AQP4+ NMOSD patients (pts.) from the N-MOmentum trial with a history of immunosuppressive therapy (IST) as compared to those without. Methods: N-Momentum (NCT02200770) was a 28-week randomized phase 2/3 trial of INEB versus placebo, with an optional Open-Label Extension (OLE) (> 2 years). In this analysis, AQP4+ participants who received INEB (through the OLE) were grouped by no history of IST beyond treatment of acute NMOSD attacks (naïve), or prior azathioprine (AZA) and/or mycophenolate mofetil (MMF) therapy. Results: Among pts. who received INEB during the study, 94 received prior AZA/MMF and 103 were immunosuppressant naïve. The annualized relapse rate (95% confidence interval [CI]) for pts. with prior AZA/MMF was 0.11 (0.07, 0.17), compared to 0.08 (0.05, 0.14) for naïve. The annualized NMOSD-related inpatient hospitalization rate (annualized rate [95% CI]) for prior AZA/MMF was 0.15 (0.08, 0.27), and 0.12 (0.06, 0.22) for naïve. The percentage of pts with ≥ 1 study drug-related treatment-emergent adverse event (TEAE) was 30.9% (29/94) in prior AZA/MMF and 47.6% (49/103) of naïve; 4.3% (4) of prior AZA/ MMF and 5.8% (6) of immunosuppressant-naïve reported ≥ 1 study drug-related serious adverse event. Conclusion: This post hoc analysis evaluating long-term outcomes of INEB in AQP4+ NMOSD pts. treated with prior AZA/MMF therapy demonstrated a similar efficacy and safety profile as pts. without prior IST.